Clinical Analysis Of Paroxysmal Kinesigenic Dyskinesia

Objective:To investigate the clinical features,the pathogenesy and the treatment of paroxysmal kinesigenic dyskinesia(PKD).Methods:We analysis the data of 25 PKD patients,who treated in our hospital for 2005.1～2007.12.Results:The onset age of PKD in this study was between 6.0 and 22.5 years old; PKD in this study occurred frequently following sudden voluntary movement,showing dystonia involving extremities,trunk or face and mostly lasting for several to tens of seconds;patients always had clear consciousness during the attack;motor function was mostly normal during the intermittent period of onset;electroencephalogram(EEG)and neuroimaging examinations were mainly normal during the attack and intermittent periods;The mean dose of cabamazipine(CBZ)is 177.27±78.62mg/d and the mean dose of oxcarbazepine(OXC)is 180.56±74.77mg/d.The control rate of CBZ is 63.64%and the control rate of OXC is 44.44%,which have no significantly difference(p=0.653)with Chi-square test.The effective rate of CBZ is 90.91%and the effective rate of OXC is 88.8%,which also have no significantly difference(p=1.000)with Chi-square test.7 patients have adverse event,among which 4 patients stop or change drugs for adverse event.Conclusion:PKD is a clinically uncommon disease.The pathogenesy of it is still unclear and the prognosis of it is a relatively benign entity.A low dose of CBZ or OXC is sufficient to manage PKD.